Core Insights - IO Biotech announced that an abstract related to its lead investigational therapeutic cancer vaccine candidate, IO102-IO103, has been accepted for poster presentation at the ESMO Congress 2024 [1][3] - The presentation will include data from a Phase 2 basket trial of IO102-IO103 in combination with pembrolizumab for treating advanced squamous cell carcinoma of the head and neck [1][3] - The ESMO Congress will take place in Barcelona from September 13-17, 2024, with the specific presentation scheduled for September 14, 2024 [3] Company Overview - IO Biotech is a clinical-stage biopharmaceutical company focused on developing immune-modulating therapeutic cancer vaccines using its Twin® platform [1][7] - The company is advancing IO102-IO103 through clinical trials and has received breakthrough therapy designation from the FDA for treating advanced melanoma [7][8] - IO102-IO103 is designed to target both tumor cells and immune-suppressive cells in the tumor microenvironment by activating T cells [11] Clinical Trials - The ongoing clinical trials include a pivotal Phase 3 trial investigating IO102-IO103 in combination with pembrolizumab versus pembrolizumab alone in patients with advanced melanoma [11] - A Phase 2 basket trial is also being conducted to evaluate IO102-IO103 in combination with pembrolizumab as a first-line treatment for solid tumors [13] - The trials are sponsored by IO Biotech in collaboration with Merck, which supplies pembrolizumab [12][13]
IO Biotech Announces New Head and Neck Cohort Data Accepted for Presentation at ESMO Congress 2024